Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis
The present study was sponsored by Genentech. No compensation was provided to the authors in exchange for production of the present manuscript. J.S.W., M.S.W., M.W.K., and W.J.M. have previously received honoraria from Genentech for serving as members of the North American Scientific Advisory Group for the Epidemiologic Study of Cystic Fibrosis, and their respective institutions previously received grant support from Genentech for participating in the study. J.S.W., M.W.K., and W.J.M. have served as consultants for Genentech. J.S.W. was previously an employee of Genentech. D.J.P. is an employee of ICON Clinical Research, which was paid by Genentech for providing analytical services for the present study. The decision to submit the manuscript was made by the authors and was approved by Genentech.
ABSTRACT
Objectives:
The aim of the present article was to determine the prevalence of liver involvement in Hispanic patients with cystic fibrosis (CF) and identify associations with age and severity of liver involvement.
Methods:
We used 1994–2005 Epidemiologic Study of CF data to compare abnormal liver findings between Hispanic and non-Hispanic white patients with CF.
Results:
Of 30,727 patients with CF, 5015 had liver involvement. Of 1957 Hispanic patients, 20.8% had liver involvement compared with 16.0% of 28,770 non-Hispanic white patients (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.23–1.54). This higher prevalence of liver involvement persisted after adjusting for demographics and meconium ileus and was especially high in the first year of life (adjusted OR 3.14, 95% CI 2.27–4.35). Ten percent of infants with only elevated liver enzymes progressed to more severe liver disease.
Conclusions:
The Hispanic population with CF has more liver involvement (both elevated liver enzymes and clinical liver disease) than the non-Hispanic white population with CF, especially during the first year of life.
